Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30727555 | 1.00 | TSHR (0.47) | TSHRTP53EGLN1EGLN3TDP1 | |
| SCHEMBL188135 | 1.00 | TSHR (0.47) | TSHRTP53EGLN1EGLN3TDP1 | |
| SCHEMBL14860698 | 0.77 | TSHR (0.45) | TSHRTP53EGLN1EGLN3TDP1 | |
| SCHEMBL31053383 | 0.77 | LDHA (0.32) | LDHALDHB | |
| SCHEMBL14860699 | 0.77 | TSHR (0.45) | TSHRTP53EGLN1EGLN3TDP1 | |
| SCHEMBL14860697 | 0.77 | TSHR (0.45) | TSHRTP53EGLN1EGLN3TDP1 | |
| SCHEMBL29427291 | 0.75 | LDHA (0.30) | LDHALDHB | |
| SCHEMBL919464 | 0.75 | LDHA (0.30) | LDHALDHB | |
| SCHEMBL13637536 | 0.75 | LDHA (0.30) | LDHALDHB | |
| Maleic Acid SCHEMBL15239556 | 0.73 | TSHR (0.75) | TSHRTP53EGLN1EGLN3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12280047-B2 | Treatment of aneurysms | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4058448-B1 | HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER AG (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | US | disclosed |
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | US | disclosed |
| US-20230143415-A1 | TREATMENT OF ANEURYSMS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| EP-4058448-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
| US-11376248-B2 | Treatment of aneurysms | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11254644-B2 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | TES PHARMA S.R.L. (IT) | 2022-02-22 | — | — | US | disclosed |
| US-20160364520-A1 | MAMMALIAN CELL LINE MODELS AND RELATED METHODS | GENOMATICA, INC. | 2016-12-15 | — | — | US | disclosed |
| US-9454640-B2 | Mammalian cell line models and related methods | INTREXON CEU, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| WO-2016030534-A1 | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2016-03-03 | — | — | WO | disclosed |
| US-20160060226-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2016-03-03 | — | — | US | disclosed |
| US-20160060226-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2016-03-03 | — | — | US | disclosed |
| US-20120185226-A1 | MAMMALIAN CELL LINE MODELS AND RELATED METHODS | GENOMATICA, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2401696-A1 | MAMMALIAN CELL LINE MODELS AND RELATED METHODS | GT Life Sciences, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110282587-A1 | COMPUTER READABLE STORAGE MEDIUMS, METHODS AND SYSTEMS FOR NORMALIZING CHEMICAL PROFILES IN BIOLOGICAL OR MEDICAL SAMPLES DETECTED BY MASS SPECTROMETRY | EMORY UNIVERSITY (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2010098865-A1 | MAMMALIAN CELL LINE MODELS AND RELATED METHODS | GT LIFE SCIENCES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-6090414-A | MIXTURE OF ANTIOXIDANT, SELENIUM AND SULFUR PEPTIDE | LIFE SCIENCE LABS, INC. (US) | 2000-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143415-A1 | TREATMENT OF ANEURYSMS | KYNU, HAAO, HCAR2 | TSHR 4479/4885TP53 2961/4885EGLN1 1896/4885 |
| US-20160060226-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | TSHR 4829/4885TP53 2489/4885EGLN1 2010/4885 |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAMTS1 | TSHR 2230/4885TP53 4354/4885EGLN1 351/4885 |
| US-12280047-B2 | Treatment of aneurysms | KYNU, HAAO, HCAR2 | TSHR 4479/4885TP53 2961/4885EGLN1 1896/4885 |
| US-11376248-B2 | Treatment of aneurysms | KYNU, HAAO, HCAR2 | TSHR 4479/4885TP53 2961/4885EGLN1 1896/4885 |
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | TSHR 4829/4885TP53 2489/4885EGLN1 2010/4885 |
| US-11254644-B2 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | ACMSD, GLS, ALDH7A1 | TSHR 4829/4885TP53 2489/4885EGLN1 2010/4885 |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAM17 | TSHR 1345/4885TP53 4448/4885EGLN1 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.